

FEDERAL ELECTION COMMISSION**Sunshine Act Meeting**

TIME AND DATE: Tuesday, December 5, 2017, at 10:00 a.m. and its continuation at the conclusion of the open meeting on December 7, 2017.

PLACE: 999 E Street NW., Washington, DC.

STATUS: This meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Compliance matters pursuant to 52 U.S.C. 30109.

* * * * *

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694-1220.

Dayna C. Brown,

Secretary and Clerk of the Commission.

[FR Doc. 2017-25961 Filed 11-28-17; 4:15 pm]

BILLING CODE 6715-01-P

FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION**Sunshine Act Notice**

November 28, 2017.

TIME AND DATE: 10:00 a.m., Thursday, December 14, 2017.

PLACE: The Richard V. Backley Hearing Room, Room 511N, 1331 Pennsylvania Avenue NW., Washington, DC 20004 (enter from F Street entrance).

STATUS: Open.

MATTERS TO BE CONSIDERED: The Commission will consider and act upon the following in open session: *Jeffrey Pappas v. CalPortland Company, et al.*, Docket No. WEST 2016-264-DM (Issues include whether the Judge erred in ruling that the operators had not discriminated against the miner by not rehiring him).

Any person attending this meeting who requires special accessibility features and/or auxiliary aids, such as sign language interpreters, must inform the Commission in advance of those needs. Subject to 29 CFR 2706.150(a)(3) and 2706.160(d).

CONTACT PERSON FOR MORE INFO: Emogene Johnson, (202) 434-9935/(202) 708-9300 for TDD Relay/1-800-877-8339 for toll free.

PHONE NUMBER FOR LISTENING TO

MEETING: 1-(866) 867-4769, Passcode: 678-100.

Sarah L. Stewart,

Deputy General Counsel.

[FR Doc. 2017-25967 Filed 11-28-17; 4:15 pm]

BILLING CODE 6735-01-P

FEDERAL RESERVE SYSTEM**Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company**

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 18, 2017.

A. *Federal Reserve Bank of Kansas City* (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Jeffrey Alan Svajgr, Omaha, Nebraska*; to acquire voting shares of Midwest Banco Corporation, and thereby indirectly acquire voting shares of Waypoint Bank, both in Cozad, Nebraska.

Board of Governors of the Federal Reserve System, November 27, 2017.

Ann E. Misback,

Secretary of the Board.

[FR Doc. 2017-25805 Filed 11-29-17; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM**Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of

the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 28, 2017.

A. *Federal Reserve Bank of St. Louis* (David L. Hubbard, Senior Manager) P.O. Box 442, St. Louis, Missouri 63166-2034. Comments can also be sent electronically to

Comments.applications@stls.frb.org:

1. *Midland States Bancorp, Inc., Effingham, Illinois*; to acquire 100 percent of the voting shares of Alpine Bancorporation, Inc., Belvidere, Illinois, and thereby indirectly acquire Alpine Bank & Trust Company, Rockford, Illinois.

Board of Governors of the Federal Reserve System, November 27, 2017.

Ann E. Misback,

Secretary of the Board.

[FR Doc. 2017-25806 Filed 11-29-17; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[60Day-18-0278]

Proposed Data Collection Submitted for Public Comment and Recommendations—National Hospital Ambulatory Medical Care Survey (NHAMCS)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice; correction.

SUMMARY: The Centers for Disease Control and Prevention (CDC) requested publication of a document in the **Federal Register**. Document 2017-25496, Proposed Data Collection Submitted for Public Comment and Recommendations—*National Hospital Ambulatory Medical Care Survey (NHAMCS)*, has been scheduled to publish on November 27, 2017. The document provided the incorrect docket number (CDC-2018-0101).

FOR FURTHER INFORMATION CONTACT:
Leroy Richardson, 1600 Clifton Road,
MS D-74, Atlanta, GA 30333; telephone
(404) 639-4965; email: omb@cdc.gov.

Correction

Correct the docket number on the
ADDRESSES line to read: Docket No.
CDC-2017-0101.

Dated: November 24, 2017.

Leroy A. Richardson,

*Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.*

[FR Doc. 2017-25778 Filed 11-29-17; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2015-E-3316 and FDA-
2015-E-3315]

Determination of Regulatory Review Period for Purposes of Patent Extension; ADVANTAME

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for ADVANTAME and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that food additive.
DATES: Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by January 29, 2018.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
May 29, 2018. See "Petitions" in the
SUPPLEMENTARY INFORMATION section for
more information.

ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before January 29,
2018. The <https://www.regulations.gov>
electronic filing system will accept
comments until midnight Eastern Time

at the end of January 29, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.

Electronic Submissions

Submit electronic comments in the
following way:

- **Federal eRulemaking Portal:**
<https://www.regulations.gov>. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to [https://
www.regulations.gov](https://www.regulations.gov) will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else's Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on <https://www.regulations.gov>.

- If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see "Written/Paper
Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as
follows:

- **Mail/Hand delivery/Courier (for
written/paper submissions):** Dockets
Management Staff (HFA-305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in "Instructions."

Instructions: All submissions received
must include the Docket Nos. FDA-
2015-E-3316 and FDA-2015-E-3315
for "Determination of Regulatory
Review Period for Purposes of Patent
Extension; ADVANTAME." Received
comments, those filed in a timely
manner (see **ADDRESSES**), will be placed
in the docket and, except for those
submitted as "Confidential
Submissions," publicly viewable at
<https://www.regulations.gov> or at the
Dockets Management Staff between 9

a.m. and 4 p.m., Monday through
Friday.

- **Confidential Submissions—**To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
"THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION." The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
<https://www.regulations.gov>. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
"confidential." Any information marked
as "confidential" will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA's posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: [https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/2015-
23389.pdf](https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf).

Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to [https://
www.regulations.gov](https://www.regulations.gov) and insert the
docket number, found in brackets in the
heading of this document, into the
"Search" box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
Rm. 6250, Silver Spring, MD 20993,
301-796-3600.

SUPPLEMENTARY INFORMATION:

I. Background

The Drug Price Competition and
Patent Term Restoration Act of 1984
(Pub. L. 98-417) and the Generic
Animal Drug and Patent Term
Restoration Act (Pub. L. 100-670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug product, human biologic product,